CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 189 enrolled
Drug / intervention
Ceftazidime-avibactamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04628572
NCT04628572N/ACompleted
CompareCT.gov

Retrospective Analysis to Characterize the Real World Use Patterns, Efficacy and Safety of Ceftazidime-avibactam in the Management of Gram Negative Infections.

Pfizer·observational·Posted Nov 13, 2020·Updated Aug 14, 2024

In Brief

An observational study evaluating Ceftazidime-avibactam for Gram Negative Infections. Completed, enrolled 189 participants across 8 sites.

Detailed Summary

The main objective of this non-interventional (retrospective) study is to describe the general treatment patterns, effectiveness, and safety of ceftazidime-avibactam in real-world settings in India. Eligible patients would be adults who have been treated with ≥ 48 hours of ceftazidime-avibactam in routine practice from 01 June 2019 to 01 April 2020. Data of 500 patients will be collected through the abstraction of hospital medical records (electronic) if available or through the individual patient medical record in case electronic records are not available.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGram Negative Infections
CountriesIndia
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedNov 13, 2020
Enrollment StartJan 29, 2021
Primary CompletionMar 11, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.6 years ago

Interventions

Ceftazidime-avibactamdrug

Non-Interventional Study